➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
AstraZeneca
Boehringer Ingelheim
McKesson
Harvard Business School

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

Patent: 8,697,071

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,697,071
Title:Identification and engineering of antibodies with variant Fc regions and methods of using same
Abstract: The present invention relates to molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc.gamma.RIIIA and/or Fc.gamma.RIIA with a greater affinity relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are useful in preventing, treating, or ameliorating symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function mediated by Fc.gamma.R is desired, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
Inventor(s): Stavenhagen; Jeffrey (Brookville, MD), Gorlatov; Sergey (Gaithersburg, MD), Rankin; Christopher (Clarksburg, MD), Tuaillon; Nadine (Gaithersburg, MD)
Assignee: MacroGenics, Inc. (Rockville, MD)
Application Number:13/524,652
Patent Claims:see list of patent claims

Details for Patent 8,697,071

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Try it Free 2025-08-10
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 2002-02-19 ⤷  Try it Free 2025-08-10
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Try it Free 2025-08-10
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Try it Free 2025-08-10
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 2017-06-22 ⤷  Try it Free 2025-08-10
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 2019-02-28 ⤷  Try it Free 2025-08-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Boehringer Ingelheim
McKesson
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.